The Alarming Rise of Early-Onset Lung and GI Cancers Coral Olazagasti, MD; Carolina Bernabe, MD

https://www.medscape.com/viewarticle/alarming-rise-early-onset-lung-and-gi-cancers-2026a1000lvr?src=

Monoclonal Gammopathy of Renal Significance Relapse-Free Survival Better With Maintenance Therapy Edited by Katie Lennon

https://www.medscape.com/viewarticle/monoclonal-gammopathy-renal-significance-relapse-free-2026a1000o0c?src= Maintenance therapy and treatment duration longer than 6 months are associated with improved relapse-free survival in patients with monoclonal gammopathy of renal significance (MGRS), according to a retrospective analysis of 50 patients. Among patients with a plasma cell clone, median relapse-free survival was not reached with maintenance therapy vs 2.9 years without maintenance.

Germline Profiling May Improve Risk Stratification in Therapy-Related Myeloid Neoplasms Edited by Gargi Mukherjee

https://www.medscape.com/viewarticle/germline-profiling-may-improve-risk-stratification-therapy-2026a1000oag?src= Researchers used germline variants to stratify therapy-related myeloid neoplasms (t-MNs) into molecularly and prognostically distinct subgroups beyond treatment-based classifications. They found that germline mutations in cancer predisposition genes identified a high-risk subgroup of t-MNs characterized by complex karyotypes and poor survival. Patients with myeloid-related germline variants or no germline mutations had more favorable outcomes.

Algorithm Rules Out Pulmonary Embolism in Patients With Cancer Ernie Mundell

https://www.medscape.com/viewarticle/algorithm-rules-out-pulmonary-embolism-patients-cancer-2026a1000o8g?src= The first randomized trial of its kind concludes that an algorithm widely used to rule out pulmonary embolism (PE) can safely be extended to patients with cancer.

Chordoma Guidance Moves Into Age of Shared Decision-Making, Staging With Molecular Biomarkers Richard Mark Kirkner

https://www.medscape.com/viewarticle/chordoma-guidance-moves-age-shared-decision-making-staging-2026a1000oa4 The Global Chordoma Consensus Group is calling for shared decision-making, more use of molecular biomarkers for staging, and refined protocols for site-specific surgery in the care of patients with primary, localized chordoma. Their new recommendations were written by a panel of 150 experts from a variety of specialties, including pathology, radiology, and surgery, who reviewed 305 articles from 2010 to 2025. The updated guidance replaces a 2015 consensus statement in which 40 chordoma experts participated. The new guidance, which was published in JAMA Oncology, is more detailed than the 2015 statement, Joseph Schwab, MD, a member of the consensus group, told Medscape Medical News.

Remedi4all Hackathon

https://remedi4all.org/resources/remedi4all-repurposing-academy/remedi4all-hackathon/ The REMEDi4ALL Repurposing Hackathon is designed to help early career researchers learn by doing. Join a small team of international trainees keen to learn about the repurposing pathway on a week-long residential course where you aim to plan the development of a repurposing candidate for a specific patient community.

Starting a patient organisation ++

https://pierrerobineurope.com/ The EURORDIS member organisation Pierre Robin Europe have published a new article, providing easy-to-follow, practical advice on setting up a rare disease patient organisation. From launching a group on Facebook to building a website, this article offers all the information you need to create a successful rare disease patient organisation. https://pierrerobineurope.com/how-to-build-a-rare-disease-patient-organization/